Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

Targeting GPR31 to treat MASH

By
  1. Sarah Crunkhorn
Access through your institution
Buy or subscribe

Metabolic dysfunction–associated steatohepatitis (MASH) is a prevalent liver disease that can lead to cirrhosis, liver cancer and liver failure. Treatment options are limited and only one disease-specific drug, resmetirom, has gained FDA approval.

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41573-025-00158-z

References

  1. Zhang, X-J. et al. Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction–associated steatohepatitis. J. Clin. Invest. https://doi.org/10.1172/JCI173193 (2025)

Download references

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links